Member Info for MoreThanMe

100% specificity for the abc-19 antibody test, so there are no false positives for example from a different virus.

As we have learnt from Novacyt, getting yourself governement contracts around the world becomes a lot easier after you have signed your first one, as you have in effect been vouched for in the eyes of other governments. As a result, I can see the abc-19 antibody test orders, increasing the demand of our other products such as our covid Visitect range of tests and future Mologic lft antigen test.

Pricesless because of the global recognition the abc-19 test now has because of UK government orders. Every company and government will now know that this is the go to gold standard rapid home antibody test. How do you put a price on that?

Through Bupa, antibody tests are currently being sold at £65 which is the Abbott test and the small print on their site states that it has a sensitivity of 87-93%, how this test is availible to the general public, I have no idea. But it highlights the importance of our test and the huge achievement of the UK-RTC to achieve 100% specificity and 97.7% sensitivity, absolutely brilliant result.

quote: "Our tests have been evaluated for their accuracy by Public Health England. The specificity of our tests was evaluated as being over 99%. The sensitivity of our tests was evaluated as being between 87-93%. No test is 100% accurate and a negative test therefore does not rule out previous COVID-19 infection."

link: "https://www.bupa.co.uk/health/payg/covid-testing"

The US government is really starting to get behind and back rapid lateral flow poc tests and yesterday the NIH announced $130m in awards to support companies in the scale up and manufacturing of these tests. It is only a matter of time before the UK government show their hand and inform the public of their progress with LFTs and how much they have been building the UK diagnostics industry.

quote: "NIH recently announced $129.3 million in scale-up and manufacturing support for these SARS-CoV-2 tests, whose aim is to deliver results at the point-of-care (POC), within a day’s time."

link: https://www.aacc.org/cln/cln-stat/2020/october/1/another-push-to-build-covid-19-testing-capacity

Also remember the some of the governments reasoning behind the creation of the UK-RTC:

quote: “As part of the government’s national testing strategy, the expertise and resources of the UK’s world-leading life sciences industries are being pooled to build a large-scale British diagnostics industry as quickly as possible.”

link: https://www.gov.uk/government/news/industry-responds-to-call-to-arms-to-build-british-diagnostics-industry-at-scale

For those that want further information on our Visitect HIV CD4 test there was a journal posted in the Journal of International Medical Research this week, further validating our CD4 test.

link: https://journals.sagepub.com/doi/full/10.1177/0300060520955028

@In2Win_2017 Here is the contents of the RNS, presentation at 2pm, Vox link in the RNS and I am sure they will host the presentation / video.

"Investor Presentation

Omega Diagnostics Group plc (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that Colin King, Chief Executive, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments (TPI) Ltd and Vox Markets.

The event will be held on Monday, 5 October 2020 at 2pm. To access the event, please register your interest at https://**********.brand.live/c/omega-diagnostics-investor-presentation

No new price-sensitive information is disclosed as part of the presentation. Within the presentation the Company provides indicative guidance on timelines for product evaluations, product supply, potential timing for first commercial sales and targeted production volumes. These timelines are for guidance purposes only and there is no guarantee that these will be met. The Company expects to keep shareholders updated regularly on progress in achieving these future milestones."

From Twitter: Due to high demand Visitect orders are on back order, so looks like there is a very strong demand for the tests.

link: https://twitter.com/MattWilton/status/1311954055166603264/photo/1

Resistance of the previous ATH of 94.98, on the 15th of Sep, break that and we will be testing £1 today.

90p to sell up we go

I was amazed it dropped back to the 70p range, but the market isn't as always as efficient as some would believe especially in smaller cap companies. £0.8925 to sell quantity here, looking forward to seeing today unfold and getting some further updates on Monday. I can imagine things on the ground must be moving very fast so I am sure Monday will be enlightening.

Not sure if it has been posted yet, but here is a scientiic paper on the Visitect CD4 test in the Journal of International Medical Research, here is the conclusion from the journal:

"VISITECT®CD4 performed well using venous blood, demonstrating its potential utility in decentralization of CD4 testing services in resource-constrained settings."

link: https://journals.sagepub.com/doi/pdf/10.1177/0300060520955028

£1.696 to sell quantity

With the exciting news and people gaining a better understand of the recent updates, I feel sentiment is starting to change here and can see this running away today. There are a lot of people waiting in the wings, that are very interested in the share, but are waiting for the share price to move up before jumping in.

Amen, we have been through this all before and look how things turned out: 33p to 240p. People need a longer time frame than the next week, companies aren't built in a few days.

Wipe out the £1.50 stop losses and head back up, my interpretation of today. Fantastic news yesterday that the company can now get the drug into the hands of those that need it and will be getting paid for it. A step on the way to approvals. It has been a hard road here, but we are starting to see the light at the end of the tunnel here. GLA

We have had so many derisking events with this company: Will the design freeze be achieved? Will the abc-19 antibody test be accurate enough? Is lateral flow testing the right technology? Do antibodies imply immunity? All these questions and risks to the company have now been cleared up and heavily derisked the invesment for me.

I am laughing that the current worry some here on this bb have is will there be demand for our tests in the middle of the worst pandemic in 100 years? There are some genuine risks to the company, like the risks stated above, but I don't see demand and sales being a risk at all.

News is starting to be digested by investors and I can see a good afternoon of trading ahead of us.

I do agree that we need some concrete update / sales update as the market is never keen on uncertainty, however the idea that we would not fill our capacity in the middle of a global pandemic, going into the winter with a second wave upon us is highly unlikely.

From the Investor meets company presentation link to a screenshot of the slide below:

- £1.1m | COVID-19 –ELISA Testing: 275k tests per week to 1m tests per week
- £3.0m | COVID-19 –LFT: 100k tests per week to 500k tests per week (£1.1m) extended to 1.0m tests per week (£1.9m)
- £0.4m | VISITECT® CD4Margin Improvement
- £2.7m | Expand Lateral Flow Product Portfolio
- £1.0m | Repayment of Overdraft Facility
- £2.3m | Working Capital estimate
-----------
- £10.5m | Total

Link: https://imgur.com/a/nHmLEdz